Recordati says the majority of its board finds the private-equity bid from CVC Capital Partners and Groupe Bruxelles Lambert to be fair, signaling progress toward a take-private. No price terms are disclosed. If the deal closes, GBL's stake could gain liquidity and value through a potential exit, subject to financing and regulatory approvals.
GBL, alongside CVC Capital Partners, has initiated a €10.7 billion cash offer for the Italian pharma firm Recordati. This acquisition could significantly enhance GBL's presence in the pharmaceutical sector, potentially increasing its revenue and market influence.
